Arif A. Awan

501 Smyth Road
Ottawa, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

Every Six-Month versus Single-Dose Adjuvant Zoledronate in Early Breast Cancer.

Journal: NEJM evidence
Published: May 26, 2026

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Journal: ESMO open
Published: January 16, 2026

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Treatment Patterns and Clinical Outcomes in Metastatic HR+/HER2- and Triple-Negative Breast Cancer in Canada: The HER2- TRENDS Study.

Journal: Advances in therapy
Published: December 05, 2025

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.

Journal: Current oncology (Toronto, Ont.)
Published: November 01, 2025

REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.

REaCT-5G: a randomized trial of bone pain with 5-day filgrastim vs pegfilgrastim for neutropenia in breast cancer.

Journal: JNCI cancer spectrum
Published: May 22, 2025

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.

Journal: Breast cancer : basic and clinical research
Published: March 21, 2025

A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study).

A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study).

Journal: NPJ breast cancer
Published: January 10, 2025

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer.

A Randomized Trial Comparing Concurrent versus Sequential Radiation and Endocrine Therapy in Early-Stage, Hormone-Responsive Breast Cancer.

Journal: Current oncology (Toronto, Ont.)
Published: June 10, 2024

A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer.

A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer.

Journal: Breast cancer research and treatment
Published: April 22, 2024

The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care.

The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care.

Journal: Current oncology (Toronto, Ont.)
Published: February 06, 2024

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study.

Does Pre-Emptive Availability of PREDICT 2.1 Results Change Ordering Practices for Oncotype DX? A Multi-Center Prospective Cohort Study.

Journal: Current oncology (Toronto, Ont.)
Published: January 18, 2024

Young Women with Breast Cancer: The Current Role of Precision Oncology.

Young Women with Breast Cancer: The Current Role of Precision Oncology.

Journal: Journal of personalized medicine
Published: October 08, 2023
Showing 1-12 of 42

Last Updated: 09/26/2026